FDA approves Sanofi's follow-on version of Lilly’s Humalog

Eli Lilly is facing the threat of competition to its big-selling short-acting insulin Humalog after Sanofi claimed full FDA approval for a rival version. ... Now Sanofi can go after one of Lilly’s big brands - Humalog made $2.1bn in sales for Lilly in

Lilly mulls divestment of its animal health operations

Off-loading Elanco could raise billions of dollars to invest in the pharma business at a time when it is facing biosimilar competition from Sanofi for its best-selling drug Humalog

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes. Sanofi's biosimilar version of Eli Lilly's mealtime insulin product Humalog has been recommended for approval in the EU, raising the prospect ... The importance of Humalog to Lilly cannot be

Surging Trulicity takes sting out of Lilly's arthritis setback

Trulicity's strong form - coupled with forecast-topping 17% growth for Lilly's insulin blockbuster Humalog to $708m and a $94m contribution from new psoriasis drug Taltz (ixekizumab) - helped Lilly boost

1 2 3 4 5 6 7 [ Next 5 results ]